

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT APPLICATION FOR LAUNCHING “MEASARTAN POTASSIUM TABLETS (美阿沙坦鉀片)” BEING ACCEPTED

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that launch application for the “Measartan Potassium Tablets* (美阿沙坦鉀片)”, with 40 mg and 80 mg as its specifications, developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, a wholly-owned subsidiary of the Group has been submitted to the National Medical Products Administration of the PRC and has been accepted. Measartan Potassium Tablets* (美阿沙坦鉀片) are used for the treatment of primary hypertension on adults.

Azilsartan medoxomil potassium is an angiotensin II receptor antagonist. After oral absorption, it is rapidly converted into the active ingredient azilsartan, which can lower blood pressure by blocking angiotensin II.

In the overall renin-angiotensin system (RAS) market, more than 80% of the market share is occupied by “sartan” monotherapy and combination drugs, especially various combination drugs. As their sales in 2022 exceeded RMB10 billion, “Sartan” antihypertensive drugs hold an important position in the entire hypertension family.

Measartan Potassium Tablets* (美阿沙坦鉀片) are Category B medicines under the National Medical Insurance* (國家醫保), with no restrictions on indications and disease types as to insurance. They have now become a first-line antihypertensive agent for treating primary hypertension on adults both domestically and internationally with significant, long-lasting and stable antihypertensive effects, stronger organ-protective effects and other advantages. The “Measartan Potassium Tablets* (美阿沙坦鉀片)” developed by the Company are submitted as a Category 4 chemical drug, when the formulations of the two specifications are basically consistent with those of reference preparations. Through pharmaceutical and

clinical (BE) studies, their quality and efficacy have reached the same level as those of reference preparations, ensuring that the medication is safe and effective for patients, with a risk-benefit ratio comparable to those of reference preparations.

“Measartan Potassium Tablets* (美阿沙坦鉀片)” is another important product of the Group, further enriching the Group’s product pipeline in the field of the circulatory system. The two specifications of 40mg and 80mg are suitable for patients with mild-to-moderate hypertension and severe hypertension respectively. The product will provide additional treatment options for adult patients of primary hypertension after launch.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 30 August 2024

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming as executive Directors, and Mr. Sze Wing Chun, Mr. Lee Kwok Tung Louis and Dr. To Kit Wa as independent non-executive Directors.

* *For identification purposes only*